Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database

被引：0
|
作者：
Megan C. Roberts
Dave P. Miller
Steven Shak
Valentina I. Petkov
机构：
[1] National Cancer Institute,
[2] Genomic Health Inc.,undefined
来源：
Breast Cancer Research and Treatment | 2017年 / 163卷
关键词：
Breast cancer; Disease-specific survival; Lymph node-positive; Oncotype DX; Recurrence Score; SEER;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：303 / 310
页数：7
相关论文
共 50 条
  • [31] Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
    Unal, Caglar
    Ozmen, Tolga
    Ordu, Cetin
    Pilanci, Kezban Nur
    Ilgun, Ahmet Serkan
    Gokmen, Erhan
    Almuradova, Elvina
    Ozdogan, Mustafa
    Guler, Niluefer
    Uras, Cihan
    Kara, Halil
    Demircan, Orhan
    Isik, Selver
    Alco, Gul
    Saip, Pinar
    Aydin, Esra
    Duymaz, Tomris
    Celebi, Filiz
    Yararbas, Kanay
    Soybir, Gursel
    Ozmen, Vahit
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [32] Physician Survey of the Effect of the 21-Gene Recurrence Score Assay Results on Treatment Recommendations for Patients With Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer
    Oratz, Ruth
    Kim, Benjamin
    Chao, Calvin
    Skrzypczak, Stanley
    Ory, Caron
    Bugarini, Roberto
    Broder, Michael
    JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (02) : 94 - +
  • [33] The Role of the 21-Gene Recurrence Score(R) Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
    Yordanova, Mariya
    Hassan, Saima
    CURRENT ONCOLOGY, 2022, 29 (03) : 2008 - 2020
  • [34] Utilization and survival benefit of radiation therapy among hormone receptor positive breast cancer patients with recurrence score from Oncotype DX testing
    Zhang, L.
    Hsieh, M-C
    Petkov, V. I.
    Wu, X-C
    Yu, Q.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] The Oncotype DX® Breast test to guide management of node-positive oestrogen receptor-positive HER2-negative breast cancer patients: the United Kingdom experience
    Battisti, N. M. L.
    Gutteridge, E.
    Mylvaganam, S.
    Parton, M.
    Ring, A.
    McGrath, S. E.
    BREAST, 2019, 44 : S17 - S17
  • [36] Comparing practice patterns and outcomes for early-stage hormone receptor-positive and node-positive breast cancer patients with high-intermediate-risk Oncotype Dx scores in the National Cancer Database.
    Tamragouri, Keerthi
    Ritz, Ethan M.
    Rao, Ruta D.
    O'Donoghue, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] The effect of Oncotype DX® Recurrence Score on treatment recommendations for geriatric patients with early stage hormone receptor positive breast cancer
    Loftus, L.
    Acs, G.
    Kiluk, J.
    Laronga, C.
    Lee, M. C.
    Soliman, H.
    Boughey, J. C.
    Acs, P.
    Gordon, L.
    Sokol, G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 : S33 - S34
  • [38] Ki-67 Image Cytometric Quantitation and Oncotype Dx Recurrence Score in Estrogen Receptor-Positive Breast Cancer
    Williams, D. J.
    Cohen, C.
    Darrow, M.
    Page, A. J.
    Chastain, B.
    Adams, A.
    MODERN PATHOLOGY, 2010, 23 : 78A - 78A
  • [39] Ki-67 Image Cytometric Quantitation and Oncotype Dx Recurrence Score in Estrogen Receptor-Positive Breast Cancer
    Williams, D. J.
    Cohen, C.
    Darrow, M.
    Page, A. J.
    Chastain, B.
    Adams, A.
    LABORATORY INVESTIGATION, 2010, 90 : 78A - 78A
  • [40] The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor-Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists
    Joh, Jennifer E.
    Esposito, Nicole N.
    Kiluk, John V.
    Laronga, Christine
    Lee, M. Catherine
    Loftus, Loretta
    Soliman, Hatem
    Boughey, Judy C.
    Reynolds, Carol
    Lawton, Thomas J.
    Acs, Peter I.
    Gordan, Lucio
    Acs, Geza
    ONCOLOGIST, 2011, 16 (11): : 1520 - 1526
12345